Please login to the form below

Not currently logged in
Email:
Password:

Syncona

This page shows the latest Syncona news and features for those working in and with pharma, biotech and healthcare.

Freeline raises £88m to accelerate haemophilia gene therapy

Freeline raises £88m to accelerate haemophilia gene therapy

Sycona the driver for UK gene therapy start-ups. Playing a key role in the flowering of gene therapy companies in the UK is London-based life sciences investment fund Syncona, ... The new funding for Freeline adds to almost £35m the company raised in a

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • European venture funding for the life science sector European venture funding for the life science sector

    New funds such as Oxford Sciences Innovation, Syncona (which listed at the start of the year and consequently increased its deployment capital) are likely to reinforce this trend going forward. ... The recent flotation of Syncona’s Nightstar

  • Pharma deals during January 2013 Pharma deals during January 2013

    in this vein this year, the Wellcome Trust announced the investment of $200m initial capital into Syncona Partners LLP a new evergreen investment company. Syncona will make investments across healthcare – device, ... Acquisition. Contraception

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Gyroscope Therapeutics appoints CEO Gyroscope Therapeutics appoints CEO

    team. Chris Hollowood, chairman of the board and chief investment office at Syncona, said: “We are extremely pleased to appoint Soraya and look forward to her leadership and extensive gene therapy

  • Anne Prener to lead Freeline Therapeutics Anne Prener to lead Freeline Therapeutics

    Chris Hollowood, chairman of Freeline Therapeutics and chief investment officer of Syncona, said: “Anne is an extremely accomplished executive with extensive experience in building and leading teams and developing haematology and

  • Edward Hodgkin elected chair of UK biotech association Edward Hodgkin elected chair of UK biotech association

    Hodgkin is currently a partner at the Wellcome Trust's independent subsidiary Syncona Partners, where his role is to create and lead new life science ventures.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics